verified SJR 0,585 · Q2 • database Scopus / SJR & Web of Science indexed

United Kingdom · Taylor and Francis Ltd.

workspace_premium Q2 — Medicine (miscellaneous) lock Subscription

Expert Review of Pharmacoeconomics and Outcomes Research

Expert Review of Pharmacoeconomics and Outcomes Research is a journal indexed in SJR in Medicine (miscellaneous) and Health Policy with an H index of 66. It has a price of 2395 €. It has an SJR impact factor of 0,585 and it has a best quartile of Q2. It is published in English. It has an SJR impact factor of 0,585.

ISSN: 1473-7167

Publisher: Taylor and Francis Ltd.

Category: Medicine (miscellaneous)

Indexation: verifiedScopus / SJR verifiedWeb of Science

open_in_new Portal NPD menu_book Guidelines NPD

schedule CountryOfPapers database fields

SJR Impact Factor trending_up

0,585 Q2

H-index 66

Acceptance rate pie_chart

29% Selective

Source Acceptance_Rate

Time to publication hourglass_top

NPD

Field NPD

Publication cost (APC) payments

2.395 € Subscription

Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

0,585

H-index

Docs (year)

132

Docs 3y

362

Total refs

6443

Cites 3y

655

Citable 3y

344

Cites/Doc 2y

1.61

Ref/Doc

48.81

Immediate OA

2395 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims

rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.

Publication speed *

Review quality *

Edition and editorial team *

Institutional email or ORCID * * Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Cost-effectiveness of alternative strategies to prevent trachomatous blindness

What's wrong with quality-of-life measures? A philosophical reflection and insights from neuroimaging

Disease management: promising, but not yet proven

Direct and indirect cost of diabetes care among patients with type 2 diabetes in private clinics: a multicenter study in Punjab, Pakistan

Determinants of costs in blood services: blood transfusion from an economic perspective

Costs of multiple myeloma and associated skeletal-related events in The Netherlands

Costs and benefits of addictive-behavior interventions

Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma

Cost-of-illness analyses for policy making: a cautionary tale of use and misuse

Cost-effectiveness of replacing NSAIDs with coxibs: diclofenac and celecoxib in rheumatoid arthritis

Cost-effectiveness of pegylated IFN-a2band -2aand ribavirin for chronic hepatitis C treatment

Cost-effectiveness of left ventricular assist devices

SHOW MORE ARTICLES

Cost-effectiveness of emergency contraceptive pills in the public sector in the USA

10th Annual Australian Health Outcomes Conference 2004: 10 years on and going strong

Cost studies in clinical trials

Cost per quality-adjusted life year and disability-adjusted life years: the need for a new paradigm

Cost effectiveness of methylphenidate versus AMP/DEX mixed salts for the first-line treatment of ADHD

Compliance with inhalatory therapy: an increasingly recognized clinical outcome

Comparing policies to enhance prescribing efficiency in Europe through increasing generic utilization: changes seen and global implications

Change and stability in the Canadian healthcare system

Antibiotics and reduced risk of COPD re-exacerbations

Advancing PROMIS's methodology: results of the Third Patient-Reported Outcomes Measurement Information System (PROMIS¬Æ) Psychometric Summit

A systematic review of the methodological quality of economic studies evaluating ophthalmic drugs

A review of the economics of adult congenital heart disease

FAQs

Expert Review of Pharmacoeconomics and Outcomes Research has an SJR of 0,585 (best quartile Q2) in the CountryOfPapers database.

Immediate OA APC is 2395 EUR. Non-OA / submission fee is 0 EUR.

The acceptance rate recorded for Expert Review of Pharmacoeconomics and Outcomes Research is 29%.

Expert Review of Pharmacoeconomics and Outcomes Research

Metrics

Name good journals. Call out predatory ones.

Researcher reviews

Best articles by citations

FAQs

What is the SJR of Expert Review of Pharmacoeconomics and Outcomes Research?

What is the APC / publication cost?

What is the acceptance rate?